Cardiol Therapeutics Inc.

TSX:CRDL.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.36 +0.67%

+$0.00 today

Market cap
$164.10M
Beta
0.48
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $1.23High $2.33

Volume 0.08M

Average 0.12M

CRDL.TO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Cardiol Therapeutics Inc.TSX: CRDL.TO

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 108.99M shares rose 31.9% year over year, ahead of the +24.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 8.7% from the prior quarter. Over 3 fiscal years it compounded at +11.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +31.9% holds above the trailing-twelve-month pace of +24.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
108.99M+8.7% QoQ
Last fiscal yearDec 2025
86.99M+21.5% YoY
LTMMar 2026
94.16M+24.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.9%——
1 year+21.5%——
3-year CAGR+11.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
86.99M CAD
Year-over-year change
+21.5%
4-year CAGR
+19.1%

Weighted Avg Shares (Diluted) vs competitors

How CRDL.TO compares with its peers on the latest reported figures

  • CRDL.TO's LTM Mar 2026 weighted avg shares (diluted) of 94.16M shares is the highest of the 3 companies compared; the peer median is 23.46M shares.
  • Its year-over-year change of +24.3% is the highest of 2, against a peer median of -1.3%.
  • Over three fiscal years its annual growth of +11.6% compares with a peer median of +34.5%.
CRDL.TO Competitors Peer median
Weighted Avg Shares (Diluted) for CRDL.TO and competitors
Company Period LTM YoY 3-year CAGR
CRDL.TOCardiol Therapeutics Inc.LTM Mar 202694.16M +24.3%+11.6%
HLS.TOHLS Therapeutics Inc.LTM Mar 202631.4M -1.3%-0.9%
MSCL.TOSatellos Bioscience Inc.LTM Mar 202615.53M —+70.0%
Peer median (excluding CRDL.TO) 23.46M-1.3%+34.5%

Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.76K0000
Cost of Revenue220.42K219.91K248.36K373.11K101.98K
Gross Profit78.76K(219.91K)(248.36K)(373.11K)(101.98K)
Gross Margin100.0%————
Research & Development10.87M18.96M14.22M14.01M14.02M
Selling, General & Admin27.87M22.37M15.56M25.89M20.2M
Operating Expenses38.74M41.34M29.54M39.9M34.32M
Depreciation & Amortization220.42K219.91K248.36K373.11K101.98K
EBITDA(38.44M)(30.71M)(27.88M)(36.3M)(34.21M)
EBITDA Margin-48812.1%————
Operating Income(45.47M)(50.34M)(29.79M)(40.28M)(34.32M)
Operating Margin-57736.3%————
Interest Income106K1.24M2.04M1.19M726.4K
Interest Expense00000
Other Income / Expenses7.03M10.41M1.66M3.6M497.42K
Income Before Tax(31.64M)(30.93M)(28.13M)(36.68M)(33.82M)
Pre-Tax Margin-40170.4%————
Income Tax Expense(6.91M)(19.41M)000
Net Income(24.72M)(11.52M)(28.13M)(36.68M)(33.82M)
Net Margin-31391.5%————
EPS (Basic)(0.57)(0.18)(0.44)(0.51)(0.39)
EPS (Diluted)(0.57)(0.18)(0.44)(0.51)(0.39)
Weighted Avg Shares43.22M62.51M64.46M71.57M86.99M
Weighted Avg Shares (Diluted)43.22M62.51M64.46M71.57M86.99M

Cardiol Therapeutics Inc.

TSX:CRDL.TO

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.